Lv5
1198 积分 2023-05-12 加入
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
2小时前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
2小时前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
2小时前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
2小时前
已完结
Giredestrant plus Everolimus in Advanced Breast Cancer
2小时前
已完结
The immunology of human breast cancer
9天前
已完结
Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
1个月前
已完结
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer
1个月前
已完结
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial
1个月前
已完结
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial
4个月前
已完结
皖公网安备34019202002308
